Study to Verify the Efficacy of a Product Containing 125 mg of TetraSOD® for the Treatment of Male Infertility
In plain words A study of tetraselmis chuii in male participants 18 to 45, run by Fitoplancton Marino, S.L.. It plans to enroll about 50 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 to 45. Conditions: Male Infertility.
- Age: 18 to 45
- Male patients with idiopathic infertility classified with asthenozoospermia, oligozoospermia or oligoasthenozoospermia after seminal assessment.
- Not achieving pregnancy after at least one year of intercourse with the same partner without protective measures
The exclusion criteria are on the listing.
What it tests, as registered
Sham; Marine microalgae Tetraselmis chuii with high Superoxide Dismutase (SOD) activity
Registered summary
TetraSOD® is a unique marine phytoplankton (Tetraselmis chuii) SOD-rich ingredient that is grown under patent-protected technology exclusively designed by the company Fitoplancton Marino, S.L. (Spain). In a previous pilot trial, the ability of TetraSOD® (dose: 250 mg/day) to improve semen characteristics in idiopathic infertile men after three months of treatment was assessed, revealing significant improvements in almost all of the analyzed parameters. The full summary is on the listing.
Where, as registered
No US site; Spain (1).